- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adam Simmons: ENLIGHTEN-2 Data Demonstrate Efficacy, Reduced Weight Gain With ALKS 3831
Data presented at the 175th Annual Meeting of the American Psychiatric Association (APA) support the potential of the investigational drug ALKS 3831 to provide the antipsychotic efficacy of olanzapine without the associated weight gain, said Adam Simmons, director of clinical program management, Alkermes. He also discussed the timing of when the data might be filed with the FDA.
Data presented at the 175th Annual Meeting of the American Psychiatric Association (APA) support the potential of the investigational drug ALKS 3831 to provide the antipsychotic efficacy of olanzapine without the associated weight gain, said Adam Simmons, director of clinical program management, Alkermes. He also discussed the timing of when the data might be filed with the FDA.
Transcript
How do the data presented at APA support the value of ALKS 3831?
Through the data that we’re presenting here at APA, we’re demonstrating the 2 things that we wanted to demonstrate with this product: that the efficacy that you see when combining samidorphan and olanzapine is similar to that known efficacy of olanzapine, and then the data that we’ll be sharing here as well, that’s going to be presented by Dr Correll tomorrow, is our ENLIGHTEN-2 data, where we’ve demonstrated clinically significant reductions in weight gain with the combination product versus olanzapine alone.
What’s the timetable for a filing with the FDA?
We’re currently putting together the data, the combined package of which we’re sharing here at APA, and we’re expecting on filing that data with the FDA later this year.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
